Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

How to Reconstitute Tesamorelin

A laboratory-focused guide to reconstituting tesamorelin, covering its identity as a GHRH analogue, the mechanics of sterile reconstitution, and the clinical research models in which it has been studied.

peptides-pro Editorial

Tesamorelin is a synthetic 44-amino-acid growth hormone-releasing hormone (GHRH) analogue, also known by the synonyms EGRIFTA and EGRIFTA WR. It belongs to the peptide class of GHRH receptor agonists. The evidence block provided for this page does not supply a sequence, molecular formula, or molecular weight, so those identifiers are not stated here. The work described in the evidence centres on the GHRH receptor pathway and its downstream effects on endogenous growth hormone secretion.

Reconstitution is the process of dissolving a lyophilised (freeze-dried) peptide powder in a suitable sterile diluent to produce a liquid solution for laboratory use. For tesamorelin, the evidence block does not specify a recommended diluent, concentration, or volume; those parameters are set by the individual laboratory protocol and the product's certificate of analysis. This page summarises what the cited research reports about tesamorelin and describes the general laboratory practice of reconstitution without providing a protocol for any specific product.

Research Studies

Tesamorelin and physical function in older adults with HIV (TRIUMPH)

The TRIUMPH study is a two-site, double-blind, randomised controlled trial of 100 sedentary older adults aged 50–80 years living with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Enrolled participants were randomised to receive tesamorelin or placebo as an adjunct to a home-based semisupervised exercise programme for 24 weeks, followed by a 24-week extension phase [1]. The trial's overall goal was to examine the combined effect of exercise and the GHRH analogue tesamorelin on physical function [1]. A related registered trial describes the same population and rationale, noting that people with HIV experience earlier impairments in physical function and earlier frailty than the general population, and that exercise alone is less effective and harder to sustain in this group [5].

Tesamorelin and liver fat in adults with fatty liver disease

A randomised, double-blind, placebo-controlled Phase II study evaluated whether daily subcutaneous tesamorelin reduces liver fat in adults with fatty liver disease. Participants received tesamorelin or matching placebo for 52 weeks, with standardised lifestyle counselling in both groups. Liver fat was quantified by MRI-proton density fat fraction (MRI-PDFF), and key safety monitoring included glucose metrics and IGF-1 [2]. This study was conducted in adults with fatty liver disease, not in people with HIV.

Tesamorelin and liver fat and histology in HIV

A separate registered trial examined tesamorelin's effects on liver fat and histology in HIV. The background notes that liver disease is a leading comorbidity of HIV infection and that nonalcoholic fatty liver disease (NAFLD) is present in approximately 30–40% of patients with HIV infection; nonalcoholic steatohepatitis (NASH) is a more severe form in which increased liver fat is accompanied by inflammation, cellular damage, and fibrosis. NAFLD is most prevalent in patients who also have increased visceral adiposity, and the investigators had previously shown that HIV-infected individuals with increased visceral adiposity generally have decreased growth hormone secretion. Tesamorelin is described as a GHRH analogue that increases endogenous growth hormone [8].

Tesamorelin and lipodystrophy in people living with HIV

A systematic review and meta-analysis evaluated the efficacy and safety of tesamorelin in people living with HIV (PLWH) with lipodystrophy receiving combined antiretroviral therapy (CART), incorporating GRADE assessment. The review describes HIV-associated lipodystrophy as a complication of CART that causes significant physical and psychological distress in PLWH, compromising treatment adherence, and identifies tesamorelin, a GHRH analogue, as a therapeutic option. The authors searched PubMed, ClinicalTrials.gov, and Scopus from inception to February 9, 2026, for randomised controlled trials evaluating tesamorelin in HIV-associated lipodystrophy [3]. A separate meta-analysis of randomised controlled trials assessed body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy [10].

Tesamorelin and peripheral nerve injury

A clinical trial evaluated the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesised that treatment with tesamorelin would result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries were randomly assigned to receive either tesamorelin treatment or no treatment, with assessments for nerve regeneration, muscle function, and sensation conducted every three months for a total of 12 months, comparing outcomes in treated versus untreated groups [6].

Tesamorelin and cognition in aging with HIV

A Phase II trial tested whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, would significantly improve memory and thinking in HIV [7]. This study was conducted in aging HIV-infected persons.

Tesamorelin formulation bioequivalence in healthy participants

A study titled "Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants" examined the bioequivalence of tesamorelin formulations in healthy participants [4]. The evidence block does not provide further detail on the study design or results.

Tesamorelin and excess visceral abdominal fat: case reports

Two clinical cases described differing presentations of excess visceral abdominal fat in people living with HIV, highlighting distinct therapeutic pathways with tesamorelin and glucagon-like peptide-1 receptor agonists. The report notes that excess visceral abdominal fat is a prevalent metabolic complication among people living with HIV-1, occurring even in individuals with normal or mildly elevated body mass index, and is associated with metabolic dysfunction and cardiovascular risk [9].

Injectable peptides in sports medicine: contextual reviews

A structured narrative review summarised contemporary human and translational evidence on injectable peptides in sports medicine, noting that clinical adoption has outpaced high-quality evidence and regulatory consensus [11]. A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance described peptides as short chains of amino acids with a pharmacological niche between small-molecule drugs and large proteins, and noted that their use in sports medicine is rapidly expanding [12]. These reviews provide context for the broader peptide category and are not specific to tesamorelin.

Reconstitution in the laboratory

The evidence block does not describe a reconstitution procedure for tesamorelin. The following general laboratory principles apply to lyophilised peptides and are presented for research-use-only context.

  • Work in a clean, designated area using aseptic technique.
  • Use a sterile diluent appropriate to the peptide's solubility; the evidence block does not specify one for tesamorelin.
  • Add the diluent slowly down the inside wall of the vial rather than directly onto the powder, then swirl gently; avoid vigorous shaking, which can cause foaming and potentially denature the peptide.
  • Inspect the resulting solution for undissolved particles before use.
  • Store the reconstituted solution according to the product's certificate of analysis and your institution's standard operating procedures.

Because the evidence block does not provide tesamorelin-specific reconstitution parameters, researchers should refer to the product's certificate of analysis and their own validated laboratory protocols.

Comparison of clinical research models

Model / populationInterventionPrimary outcome or focusCitation
Sedentary older adults (50–80) with HIV, frail or at risk, excess abdominal adiposityTesamorelin or placebo plus home-based semisupervised exercise, 24 weeks plus 24-week extensionPhysical function[1]
Adults with fatty liver diseaseDaily subcutaneous tesamorelin or placebo, 52 weeks, with lifestyle counsellingLiver fat by MRI-PDFF; safety via glucose and IGF-1[2]
People living with HIV with lipodystrophy on CARTRandomised controlled trials of tesamorelinEfficacy and safety; GRADE assessment[3]
Patients with upper extremity peripheral nerve injuryTesamorelin or no treatment, 12 monthsNerve regeneration, muscle function, sensation[6]
Aging HIV-infected personsTesamorelin plus text-messaging adherence supportMemory and thinking[7]
Healthy participantsEGRIFTA WR and EGRIFTA formulationsBioequivalence[4]

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp